Pro-Dex (NASDAQ:PDEX – Get Free Report) and Femasys (NASDAQ:FEMY – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.
Institutional & Insider Ownership
15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 47.5% of Pro-Dex shares are held by insiders. Comparatively, 12.3% of Femasys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Pro-Dex and Femasys”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Pro-Dex | $53.84 million | 3.09 | $2.13 million | $1.54 | 33.11 |
Femasys | $1.07 million | 22.26 | -$14.25 million | ($0.81) | -1.28 |
Volatility & Risk
Pro-Dex has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.83, meaning that its share price is 383% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Pro-Dex and Femasys, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Pro-Dex | 0 | 0 | 1 | 0 | 3.00 |
Femasys | 0 | 0 | 3 | 0 | 3.00 |
Pro-Dex currently has a consensus price target of $52.00, suggesting a potential upside of 1.98%. Femasys has a consensus price target of $10.00, suggesting a potential upside of 861.54%. Given Femasys’ higher possible upside, analysts plainly believe Femasys is more favorable than Pro-Dex.
Profitability
This table compares Pro-Dex and Femasys’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Pro-Dex | 9.17% | 16.74% | 9.98% |
Femasys | -1,435.77% | -141.49% | -82.30% |
Summary
Pro-Dex beats Femasys on 9 of the 13 factors compared between the two stocks.
About Pro-Dex
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
About Femasys
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.